Preclinical studies have confirmed that ATR inhibitors (e.g., VE-821, ceralasertib/AZD6738) can restore sensitivity to PARPis in BRCA1-mutated resistant cells and demonstrate synergistic antitumor activity in HGSOC patient-derived xenograft (PDX) models, even inducing complete tumor regression (85, 86). The gene discussed is BRCA1; the disease is neoplasm.